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Since the majority of studies have focused on dasatinib's effect on hematopoietic disorders there have been few studies addressing the impact of dasatinib on normal blood cells, especially in vivo.
To address this we recently investigated the effects of dasatinib on hematopoiesis in both wildtype mice and mice with a knock-in mutation in the RING finger domain of c-Cbl [11, 12] , a mutation that promotes the development of a myeloproliferative disease (MPD) [13] . In these studies we found that although dasatinib did not provide an effective therapy for c-Cbl-driven MPD, it did markedly reduced immature B-lineage cells and thymocytes. Surprisingly however dasatinib did not affect the numbers of hematopoietic stem cells (HSC) or progenitors. This was unexpected given dasatinib's ability to inhibit c-Kit, and the in vivo requirement of these cells for c-Kit signaling [14] [15] [16] . We did however find that serum from dasatinib-dosed mice showed higher levels of stem cell factor (SCF), i.e. c-Kit ligand, compared to vehicle-treated mice after 4 weeks of dosing [11] . This finding raised the possibility that perturbations to HSCs or progenitors may occur at earlier times, and that these may have been rescued by an SCF response that compensated for the inhibitory effects of dasatinib. In this study we find that dasatinib induces the transient
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT

5
Cardiac or tail vein blood was collected for serum and analyzed for levels of stem cell factor and FLT3 ligand (Quantikine Kit, R&D Systems Inc, Minneapolis, MN), or interferon-α (Platinum ELISA, eBioscience, San Diego, CA).
Statistical analyses
For days 1, 8 and 16 of dosing time-courses n=3 for vehicle, and 3, 4 and 5 respectively for dasatinib. For days 2 and 4 of dosing numerous experiments were performed. For analysis of the forward scatter of viable cells six experiments were performed with a total n=19 for both vehicle and dasatinib-dosed mice. For Ki-67, pS6 and pErk data n=9 from three experiments. For 7AAD
DNA cell cycle analysis n=10 from three experiments for day 2 of dosing, and n=17 from five experiments for day 4. For BrdU analysis n=6 from two experiments for day 2, and n=3 from a single experiment for day 4. For imatinib experiments n=4 for vehicle and imatinib dosed mice on days 2 and 4. For 5-FU treatment two experiments were performed with n=8 for both vehicle and dasatinib-primed mice. To validate significance we used unpaired two-sided Student's t-tests for single experiments, or 2-way ANOVA where experiments were repeated (Prism 5, GraphPad Software). P values less than 0.05 were considered statistically significant. All statistical data are presented as means ± standard errors.
RESULTS
Dasatinib dosing induces the transient activation of quiescent long-term HSCs
From our previous studies of both wild-type C57BL/6 mice and c-Cbl RING finger mutant mice we observed that dasatinib did not reduce HSC numbers after 4 weeks of daily dosing [11, 12] . To investigate this further we analyzed C57BL/6 mice over a 16-day time course of twice daily dosing of 15 mg/kg of dasatinib, or vehicle, to determine whether dynamic, yet transient, effects published procedures [17, 18] . Strikingly, after 2 and 4 days of dasatinib dosing we observed significant increases in cell size and the induction of Ki-67 expression within the LT-HSC population ( Fig. 1A and B) . By days 8 and 16 the population of large LT-HSCs had returned to vehicle-treated sizes, and consistent with this the proportion of Ki-67 + cells was also markedly reduced. This time course analysis therefore demonstrated that dasatinib induces a transient activation LT-HSCs. Additional cohorts of mice were dosed for 2 and 4 days to determine cell cycle DNA profiles (Fig. 1C ). These studies confirmed that LT-HSCs from dasatinib-dosed mice were induced to cycle by exhibiting a significant increase in the percentage of cells in S, G2 and M phases of the cell cycle.
These analyses indicated that dasatinib promotes the proliferation of HSCs, however to determine whether HSCs continue to cycle more rapidly after 2 and 4 days of dasatinib dosing we injected mice with 5-bromodeoxyuridine (BrdU) 3 hours before harvesting bone marrow cells. These experiments involved the analysis of BrdU incorporation into the DNA of FLT3 negative LSK cells, rather than CD150 + CD48 -LSK cells. This modified approach was necessary because of technical difficulties associated with our inability to detect CD150 + cells that were stained prior to or following fixing and permeabilization. By excluding the highly proliferative FLT3 positive
MPPs the LSK cells are more highly enriched for quiescent cells than the total LSK population.
The analysis showed that mice dosed with dasatinib for 2 or 4 days exhibited a greater increase in the proportion of FLT3 negative LSK cells that incorporated BrdU compared to vehicle dosed mice (Fig. 1D) . Thus, the BrdU incorporation data suggests that HSCs continue to cycle more actively after 2 or 4 days of dasatinib exposure. Fig. 1F ). Significantly, we observed that c-Kit lo cells responded to dasatinib dosing through an induction in cell size, Ki-67 expression, and an increase in the proportion of cells in S, G2 and M phases of the cell cycle (Fig. 1E , F and G).
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In contrast to the in vivo effects of dasatinib, we found that in vitro treatment with 128 nM of were also analyzed ( Fig. 2D-F Figure 3A) . A slight increase in was not surprising that dasatinib dosing did not markedly enhance this activity.
Short-term dasatinib dosing does not alter the repopulating ability of HSCs
To determine whether the transient activation of HSCs affects their ability to repopulate lethally irradiated recipient mice we dosed B6.CD45.1 mice twice daily with dasatinib or vehicle for 2 or 4 days before harvesting bone marrow. The bone marrow cells from the dosed mice were mixed equally with competitor bone marrow from an untreated B6.CD45.2 mouse, and a total of 10 6 cells were injected into irradiated B6.CD45.1 recipients (Fig. 3A) . Peripheral blood from the four groups was analyzed by flow cytometry at 10 and 21 weeks after transplantation to determine the
proportional contribution by each of the donor bone marrows. We found no significant difference between the contributions by untreated and treated donor bone marrows in repopulating either the myeloid or B lymphoid lineages (Fig. 3B ). Thus HSCs from dasatinib-dosed mice do not appear to be functionally altered in their ability to establish and maintain hematopoiesis.
Dasatinib dosing results in a loss of LK cells expressing high levels of c-Kit
The above data does not distinguish whether the effects of dasatinib on HSC proliferative activity are direct or indirect. A possible explanation for an indirect effect is that the HSCs are responding to replenish bone marrow cells that are lost due to dasatinib-induced toxicity. To support this possibility we found a significant loss of bone marrow cells by days 2 and 4 of dasatinib dosing.
Interestingly, a partial recovery of cell numbers occurred by day 8, and a recovery approaching vehicle-treated levels was evident by day 16 (Fig. 4A) . Importantly the timing of the recovery in the bone marrow coincided with HSCs returning to a predominantly quiescent state ( Fig. 1A and B). These findings provide support for an indirect effect on HSCs in that they are transiently responding to replenish bone marrow cellularity. 
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Since LK cells are enriched for committed progenitors we determined whether there was a specific progenitor population that was depleted by dasatinib. We examined cell-surface markers that define common myeloid progenitors (CMPs), granulocytye-macrophage progenitors (GMPs) and megakaryocyte-eythroid progenitors (MEPs) after two days of dosing with dasatinib or vehicle.
We found no significant differences among these populations suggesting that dasatinib was equally potent in deleting all three populations of progenitors (data not shown). 
Dasatinib dosing causes a marked induction of Sca-1 expression
An additional effect of dasatinib on the phenotype of lineage negative cells was a marked induction of Sca-1 expression (Fig. 4E ). The increase in Sca-1 expression can also be seen in the Sca-1 vs c-Kit flow cytometry profiles from mice dosed for 2 days with either vehicle or dasatinib
As with other phenotypic changes associated with dasatinib the effect was transient, peaking at days 2 and 4, and returning to vehicle-treated levels by days 8 and 16. An increase in Sca-1 expression, albeit more profound, has also been observed in mice where type 1 interferons are induced following treatment with poly I:C [21, 22] . In one of these studies the increase in Sca-1 expression was clearly evident in c-Kit + CD48 -CD150 + gated cells [22] , and this effect was also M A N U S C R I P T
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11 seen in mice dosed for 2 and 4 days with dasatinib ( Fig. 4F ). These cells encompass LT-HSCs examined in Fig. 1 , and therefore the aberrant induction of Sca-1 expression provides further evidence that these cells are profoundly affected by dasatinib dosing. Whether the increase in Sca-1 has a functional role is not known.
Dasatinib induces stem cell factor production and promotes the induction of phospho-S6
A possible contributor to the proliferative activity of HSCs from mice dosed with dasatinib is the induction of SCF. To examine this possibility sera from mice dosed with dasatinib or vehicle for 1 to 16 days were analyzed by ELISA. We found that SCF was increased from day 1 of dasatinib dosing, and, unlike the transient cellular effects, remained elevated at day 16 ( Fig. 5A ). We also analyzed sera from B6 mice that had been dosed daily with dasatinib for 4 weeks and observed a similar sustained level of SCF (Fig. 5A ). Analysis of FLT3 ligand found that this hematopoietic growth factor was also elevated in response to dasatinib (Fig. 5B ), albeit significantly lower than the levels induced in mice following dosing with the FLT3 inhibitor quizartinib [20] . Since HSC proliferation and Sca-1 induction occurs in mice exposed to type 1 interferons, we also examined interferon α levels, however no evidence of induction by dasatinib was found (data not shown).
Thus it appears that the similar phenotypic effects caused by dasatinib and poly I:C may involve distinct mechanisms.
To further investigate the activation status of HSCs from dasatinib dosed mice we analyzed signaling by the PI 3-kinase and Ras pathways by staining LSK cells with pS6 and pErk antibodies respectively. The flow cytometry analysis showed a transient induction of pS6 on days 2 and 4, but no evidence of pErk induction ( Fig. 5C and D) . A significant level of activation of pS6 was also evident in LK cells on days 2 and 4 (Fig. 5F) . Thus it appears that LK cells, that were not lost M A N U S C R I P T
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12 by dasatinib dosing, were capable of responding to growth factors produced at this time. An increase in pS6 was also observed in Lin -c-Kit -bone marrow cells on day 4 of dasatinib dosing (Fig. 5G ). These cells express neither c-Kit nor FLT3, suggesting that activation of these cells is likely to be mediated by growth factors other than SCF and FLT3 ligand.
Imatinib causes a loss of c-Kit + cells but does not induce an HSC proliferative response
Since imatinib is another well-characterized and widely used c-Kit inhibitor we examined its effects on c-Kit + cells and HSC proliferation. Mice were dosed with 100 mg/kg of imatinib twice daily for 2 or 4 days before analysis. This dose approximates 500 mg twice daily for humans, which is slightly higher than the 400 mg twice-daily dose recommended for patients in accelerated or blast crisis phases of CML [23] . We found that imatinib caused a decrease in LK cells at days 2 and 4 ( Fig. 6A and B) , and this effect was more pronounced when focused on the loss of c-Kit hi cells ( Fig. 6C and D) . These findings were similar to, but not as profound, as the depletion observed in dasatinib-dosed mice at days 2 and 4 (compare with Fig. 4D and E). Most telling however, imatinib did not markedly enhance the proliferation status of LT-HSCs ( 
DISCUSSION
The key finding from this study is that dasatinib promotes the transient activation of quiescent
HSCs. This finding was unexpected given that dasatinib is an inhibitor of c-Kit signaling and has the ability to arrest the proliferative activity of many cell types [24] [25] [26] . However, these studies investigating dasatinib's ability to promote cell cycle arrest were carried out in vitro, highlighting the importance of studying animal models to reveal more biologically relevant outcomes. HSC proliferation by transiently reducing the expression and activity of many genes that enforce quiescence [21] . It is therefore possible that dasatinib's ability to inhibit Src family kinases could be suppressing multiple HSC quiescence-enforcing mechanisms, rather than activating the cell cycle machinery by growth factor stimulation. This possibility should be investigated in future studies given the inability of imatinib, which does not inhibit Src family kinases, to promote HSC proliferation.
As mentioned above the effects we observed on HSCs were unexpected, and at present we do not have an explanation why the inhibitory effects of dasatinib appear unable to block the transient proliferative activity of HSCs. The challenge for an explanation is also confounded by the assumption that dasatinib's inhibitory affects would act on these cells before a growth factor response could be triggered. Thus, more investigation into the mechanism of this early response is required.
This study also raises questions about whether the findings can contribute towards a better understanding of how to more effectively combine dasatinib with cytotoxic drugs. Determining how to optimize the administration of chemotherapy with tyrosine kinase inhibitors is an important area of investigation, and a recent study revealed that dasatinib in combination with cytarabine and doxorubicin enhanced chemotherapy-induced targeting of primary murine acute myeloid leukemia (AML) stem cells [28] . This study provided support for the importance of clinical trials investigating whether the addition of dasatinib to chemotherapeutic regimens can enhance the targeting of AML leukemia stem cells [29, 30] . From our data we propose that dasatinib priming before chemotherapy should be investigated as an approach that could optimize this combinational therapy. Figure 1 . Results are expressed as means ± standard errors. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 using 2-way ANOVA. errors. *P < 0.05, **P < 0.01, ***P < 0.001 using the unpaired Student's t test or 2-way ANOVA. as means ± standard errors. *P < 0.05, **P < 0.01, ***P < 0.001 using 2-way ANOVA.
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HIGHLIGHTS
• Dasatinib dosing of mice transiently activates quiescent hematopoietic stem cells.
• This activation corresponds with an induction of stem cell factor.
• 5-Fluorouracil killing of hematopoietic stem cells is enhanced following dasatinib dosing.
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1 .05, **P < 0.01, using the unpaired Student's t test or 2-way ANOVA. Overall, the data shows that dasatinib dosing does not promote the death of LSK cells. The most profound effect we observed was a decrease in Annexin V + 7-AAD + CD150 + LSK cells from dasatinib dosed mice at day one. We also observed a slight but significant increase in Annexin V + 7-AAD -CD150 -LSK cells from dasatinib dosed on day two.
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